Rachel McMinn, Chief Strategy Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 257 shares at $121.78 ($31K) on 2017-07-03, disclosed to the SEC on 2017-07-05.
Open-market sale of $31k ICPT by Chief Strategy Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| ICPT | SELL | 2017-10-04 | $17K | — | Filing → |
| ICPT | SELL | 2017-08-02 | $16K | — | Filing → |
| ICPT | SELL | 2017-05-03 | $13K | — | Filing → |